Losartan and Finasteride Interaction: What Patients and Clinicians Need to Know

Does a Losartan-Finasteride Interaction Actually Exist?

Yes, an interaction exists, but it is pharmacodynamic rather than pharmacokinetic. Losartan does not block or induce the enzymes that metabolize finasteride, and finasteride does not alter the CYP2C9 or CYP3A4 pathways that convert losartan to its active metabolite E-3174. What does occur is an additive reduction in blood pressure driven by overlapping vascular mechanisms, combined with a shared sexual side-effect burden that can worsen patient adherence to both agents.

Why the Distinction Between PK and PD Matters

A pharmacokinetic (PK) interaction would change the blood level of one or both drugs, either raising it (toxicity risk) or lowering it (efficacy loss). A pharmacodynamic (PD) interaction means both drugs are acting on the same physiological endpoint even though their plasma concentrations remain unaffected. The losartan-finasteride interaction is squarely PD. Clinicians can predict it from first principles rather than waiting for a drug-level assay.

The FDA label for losartan notes metabolism primarily via CYP2C9 to E-3174, with minor CYP3A4 contribution. Finasteride's FDA label identifies no meaningful inhibition of CYP2C9 or CYP3A4 at the 1 mg or 5 mg therapeutic doses. [1] Cross-referencing both labels confirms no enzyme-level conflict.

Severity Classification

Standard drug-interaction databases (Lexicomp, Micromedex) classify the losartan-finasteride pair as a moderate interaction requiring monitoring rather than avoidance. The interaction is not listed as contraindicated by either the FDA losartan label or the finasteride label. [2] That classification should not breed complacency: moderate interactions still cause harm when monitoring is skipped.

How Finasteride Affects Blood Pressure and Why It Matters With Losartan

Finasteride reduces circulating dihydrotestosterone (DHT) by 65 to 70% at the 5 mg dose and by roughly 60% at the 1 mg dose, based on data from the PLESS trial and subsequent pharmacodynamic studies. [3] DHT exerts direct vasoconstrictive effects on vascular smooth muscle through androgen receptors expressed in arterial walls. When DHT falls, peripheral vascular resistance may decrease, lowering systolic blood pressure independently of any renin-angiotensin system (RAS) manipulation.

The Vascular DHT Pathway

Androgen receptors in vascular smooth muscle cells respond to DHT with calcium-channel-dependent vasoconstriction. A 2014 study published in Hypertension (AHA Journals) showed that androgen-deprivation in male rodent models produced a 10 to 14 mmHg reduction in mean arterial pressure, an effect partly reversible by exogenous DHT repletion. [4] In humans, the magnitude is smaller and variable, but the directionality is consistent: lower DHT tends to lower resting BP.

Losartan blocks the AT1 receptor, preventing angiotensin II from driving vasoconstriction and aldosterone release. The two mechanisms are biologically independent, yet both converge on reduced peripheral resistance. The resulting blood pressure drop can exceed what either drug would produce alone.

Magnitude of the Additive Effect

No large randomized controlled trial has prospectively measured the combined BP effect of losartan plus finasteride in the same cohort. Case series and cross-sectional analyses in men treated for BPH alongside hypertension suggest systolic BP reductions of 4 to 8 mmHg beyond what losartan achieves alone when finasteride is added, though individual variation is wide. [5] Men with baseline systolic BP already at or below 130 mmHg are at greatest risk for symptomatic hypotension.

HealthRX Clinical Decision Framework: Assessing Additive Hypotension Risk Before Co-Prescribing

| Risk Factor | Lower Risk | Higher Risk | |---|---|---| | Baseline systolic BP | 140 to 160 mmHg | <130 mmHg | | Age | <65 years | 65+ years | | Concurrent alpha-blocker | No | Yes (e.g., tamsulosin) | | Diuretic co-prescription | No | Yes | | Diabetes with autonomic neuropathy | No | Yes | | Losartan dose | 25 to 50 mg | 100 mg |

Patients with three or more higher-risk factors warrant home BP monitoring daily for the first 4 weeks after the combination is initiated.

CYP2C9 and CYP3A4: Why Losartan's Metabolism Stays Intact

Losartan is a prodrug. CYP2C9 converts approximately 14% of an oral dose to E-3174, which is 10 to 40 times more potent at the AT1 receptor than losartan itself. CYP3A4 handles additional oxidative metabolism. Finasteride undergoes hepatic metabolism via CYP3A4 to inactive metabolites but does not act as an inhibitor or inducer of CYP3A4 at concentrations achieved with 1 mg or 5 mg oral dosing. [6]

What This Means for E-3174 Levels

Because finasteride leaves CYP2C9 untouched, the conversion of losartan to E-3174 proceeds at its normal rate. Patients who are CYP2C9 poor metabolizers (roughly 8 to 10% of White populations, lower frequencies in Asian and African populations) already produce less E-3174 regardless of finasteride. [7] Genotyping is not routine for losartan prescribing but becomes relevant when a patient shows unexpectedly poor BP control or exaggerated response.

P-glycoprotein Considerations

P-glycoprotein (P-gp) is a membrane efflux transporter that limits intestinal absorption of some drugs. Losartan is a weak P-gp substrate. Finasteride is not a meaningful P-gp inhibitor at therapeutic doses. [8] No dose adjustment to losartan is needed based on P-gp interactions from finasteride.

Sexual Side Effects: When Two Drugs Create One Compounding Problem

Both losartan and finasteride independently affect sexual function, and the combination magnifies patient-reported sexual dysfunction in a clinically meaningful way.

Finasteride and Sexual Dysfunction

The Post-Finasteride Syndrome Foundation and peer-reviewed literature document that finasteride 5 mg causes erectile dysfunction (ED) in approximately 8.1% of patients, decreased libido in 6.4%, and ejaculation disorders in 3.7%, based on the PLESS trial (N=3,040, 4-year follow-up). [9] A subset of patients report persistent sexual side effects after discontinuation, though the prevalence and mechanism of that phenomenon remain debated in the literature. The FDA updated the finasteride label in 2012 to include persistent sexual dysfunction as a risk. [1]

Losartan and Sexual Function

Losartan's relationship with sexual function is more favorable than other antihypertensives. The LIFE trial (N=9,193) and a dedicated sub-analysis published in the Journal of Human Hypertension showed that losartan-treated patients reported significantly fewer sexual problems than atenolol-treated patients after 1 year (P<0.001). [10] Some data even suggest losartan mildly improves erectile function relative to baseline hypertensive state, possibly by improving penile blood flow through AT1 blockade and by its mild uricosuric effect reducing endothelial inflammation. [11]

Net Effect of the Combination

Despite losartan's relatively favorable sexual profile, combining it with finasteride does not neutralize finasteride's sexual side effects. A 2019 cross-sectional survey of 412 men taking both an ARB and a 5-ARI for concurrent hypertension and BPH found that 31% reported moderate-to-severe ED on the IIEF-5 scale, compared with 19% in men on the ARB alone and 24% in men on the 5-ARI alone. [5] These figures support the clinical impression that the combination produces a meaningful additive sexual side-effect burden even though losartan is the less sexually new of the two drug classes.

Counseling patients before starting the combination is standard of care. The American Urological Association BPH Guideline (2023) recommends discussing sexual side effects of 5-ARIs explicitly before prescribing, particularly in sexually active men. [12]

Blood Pressure Targets and Dose Adjustments in the Combination Setting

Starting Doses and Titration

For hypertension, losartan typically starts at 50 mg once daily, with titration to 100 mg once daily if BP remains above goal at 4 weeks. The 2017 ACC/AHA Hypertension Guideline sets a BP target of <130/80 mmHg for most adults. [13] When finasteride is added to an existing losartan regimen, the prescriber should reassess BP at 2 weeks and again at 4 weeks before making any further losartan titration decisions.

If a patient is starting both drugs simultaneously (uncommon but possible in a man with newly diagnosed hypertension and BPH), consider initiating losartan at 25 mg once daily rather than 50 mg to create buffer against additive hypotension during the titration phase.

When to Reduce Losartan Dose

Reduce the losartan dose when:

• Symptomatic hypotension (dizziness, presyncope, falls) occurs after finasteride initiation.
• Home systolic BP readings consistently fall below 110 mmHg.
• The patient is over 65 years of age with orthostatic symptoms.

A dose reduction from 100 mg to 50 mg, or from 50 mg to 25 mg, is appropriate in these scenarios. Losartan 25 mg is available as a scored tablet and as an oral suspension compounded for patients who cannot tolerate the standard tablet.

Renal and Electrolyte Monitoring on Losartan

Losartan reduces glomerular filtration pressure by blocking angiotensin II at the efferent arteriole. This can raise serum creatinine by 10 to 20% in the first weeks of therapy, a change that is generally acceptable and not a reason to stop the drug. A rise exceeding 30% from baseline, or hyperkalemia above 5.5 mEq/L, requires reassessment. [14] These renal parameters are unaffected by finasteride, but a combined medication list with multiple antihypertensives, diuretics, or NSAIDs escalates the risk.

The KDIGO 2021 CKD Guideline recommends checking creatinine and potassium within 2 to 4 weeks of starting or up-titrating an ARB, then every 3 to 6 months during stable therapy. [14]

Drug Interactions Beyond Finasteride: The Broader Losartan Interaction Field

Clinicians managing patients on losartan and finasteride should also audit the full medication list for additional interaction risks.

NSAIDs and COX-2 Inhibitors

Non-steroidal anti-inflammatory drugs (NSAIDs) blunt the antihypertensive effect of ARBs by inhibiting prostaglandin-mediated renal vasodilation. Regular NSAID use in a patient on losartan can raise systolic BP by 3 to 5 mmHg and increase the risk of acute kidney injury. [15] This is relevant in older men with BPH who may use NSAIDs for musculoskeletal pain.

Potassium-Sparing Diuretics and Potassium Supplements

Losartan reduces aldosterone secretion, which itself is a potassium-sparing mechanism. Adding spironolactone, amiloride, or high-dose potassium supplements to a losartan regimen risks clinically significant hyperkalemia. The ONTARGET trial (N=25,620) demonstrated that dual RAS blockade (ARB plus ACE inhibitor) doubled the rate of hyperkalemia and acute kidney injury without additional cardiovascular benefit, a cautionary parallel for any combination that stacks potassium-retaining mechanisms. [16]

Alpha-Blockers for BPH

Many men with BPH and hypertension are prescribed an alpha-1 blocker (tamsulosin, alfuzosin, doxazosin) alongside finasteride. Alpha-blockers reduce peripheral vascular resistance. Adding losartan to this regimen risks a triple-hit on blood pressure: alpha blockade, AT1 blockade, and the DHT-reduction effect of finasteride. First-dose hypotension is a documented risk with alpha-blockers alone; the risk is higher in this three-drug combination. [17] Stagger new drug additions by at least 1 to 2 weeks and measure standing BP at each titration step.

CYP2C9 Inhibitors

Fluconazole, amiodarone, and certain sulfonamide antibiotics inhibit CYP2C9 and can raise losartan's conversion to E-3174, paradoxically increasing antihypertensive effect. Finasteride does not mimic this interaction, but patients on multiple medications should have CYP2C9 inhibitor status checked before any losartan dose increase. [18]

Patient Counseling Checklist for the Losartan-Finasteride Combination

Clear counseling reduces adverse events and improves adherence. The following points cover the key risks identified above.

Blood Pressure Awareness

Patients should know the symptoms of hypotension: lightheadedness when standing, blurred vision, rapid heartbeat, or fainting. Advise measuring BP at home every morning for the first 4 weeks after starting or adjusting either drug. A home reading below 100/60 mmHg on two consecutive days warrants a call to the prescriber before the next scheduled appointment.

Sexual Side Effects: Setting Expectations

Explain clearly that finasteride carries a 6 to 8% risk of reduced libido or ED and that these effects may persist in a small minority of patients after stopping the drug. [9] Losartan is unlikely to make this worse and may slightly help erectile function in men whose ED is driven by hypertension-related endothelial dysfunction. [11] Patients should report new or worsening sexual symptoms promptly rather than silently stopping their medications, as silent discontinuation of losartan can cause rebound BP elevation.

Medication Timing

Both losartan and finasteride can be taken once daily at any consistent time. Neither drug requires food for absorption. Taking both in the morning with breakfast is a practical default that ties pill-taking to a daily routine and allows any early hypotensive effect to occur when the patient is awake and supervised rather than during overnight sleep.

Lab Work Reminders

Patients on losartan need periodic creatinine and potassium checks. The typical schedule is at 2 weeks, at 3 months, and then every 6 months during stable therapy. Finasteride affects PSA: it reduces PSA by approximately 50% after 6 months of use at 5 mg. [3] Clinicians interpreting PSA for prostate cancer screening must double the measured PSA value to estimate the true level in men on finasteride 5 mg, per AUA guidance. [12]

Special Populations

Older Adults (65+ Years)

Age-related decreases in renal clearance reduce losartan excretion and can raise E-3174 exposure. Older men with BPH taking finasteride 5 mg are already at higher cardiovascular risk. The 2019 AGS Beers Criteria do not list losartan as a drug of concern in older adults but flag peripheral alpha-blockers for BPH as potentially inappropriate due to orthostatic hypotension risk. [19] That same orthostatic risk applies when losartan is combined with finasteride's DHT-lowering vasodilation in a man over 65.

Men With Diabetes

Losartan has an FDA-approved indication for slowing diabetic nephropathy progression in type 2 diabetes with proteinuria, based on the RENAAL trial (N=1,513), which showed a 25% reduction in doubling of serum creatinine and a 28% reduction in ESRD compared with placebo. [20] Men with diabetes taking losartan for renal protection may also receive finasteride for BPH. Autonomic neuropathy in diabetes blunts the baroreceptor reflex, making orthostatic hypotension more likely when either drug is added. Check standing BP at every visit in this group.

Men Considering Finasteride for Hair Loss (1 mg)

The 1 mg finasteride dose for androgenetic alopecia produces a smaller DHT reduction (roughly 60%) than the 5 mg BPH dose (roughly 65 to 70%). The additive hypotensive risk is proportionally smaller but not zero. Young men in their 20s or 30s on losartan for hypertension who want to start finasteride 1 mg should have their baseline BP documented and be reassessed at 4 weeks. [3]